Matthijs M. Versteegh

Diemen, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study.

Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study.

Journal: Frontiers in neurology

Published: January 08, 2026

Antiarrhythmic drugs vs catheter ablation as rhythm control for atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.

Antiarrhythmic drugs vs catheter ablation as rhythm control for atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials.

Journal: Heart rhythm

Published: November 26, 2025

The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation.

The Cost Utility of Rhythm Control Treatment Sequences in Patients with Atrial Fibrillation: Anti-arrhythmic Drugs Versus Catheter Ablation.

Journal: PharmacoEconomics

Published: November 24, 2025

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers.

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers.

Journal: BMJ open ophthalmology

Published: October 14, 2025

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers.

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers.

Journal: BMJ open ophthalmology

Published: October 14, 2025

How sustainable is our oncological care?

How sustainable is our oncological care?

Journal: Nederlands tijdschrift voor geneeskunde

Published: September 04, 2025

Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease.

Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease.

Journal: PharmacoEconomics

Published: July 31, 2025

Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study.

Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study.

Journal: Clinical and translational radiation oncology

Published: July 09, 2025

Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine.

Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine.

Journal: Multiple sclerosis and related disorders

Published: June 05, 2025

Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis.

Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis.

Journal: Gastro hep advances

Published: March 11, 2025

Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.

Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 11, 2024

Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study.

Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study.

Journal: Clinical and translational radiation oncology

Published: May 22, 2024

Showing 1-12 of 65

Last Updated: 09/26/2026